<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): JANUARY 13, 1994
- ----------------------------------------------------------
THE COOPER COMPANIES, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
------------------------
<TABLE>
<S> <C> <C>
Delaware 1-8597 94-2657368
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
</TABLE>
ONE BRIDGE PLAZA, 6TH FLOOR, FORT LEE, NEW JERSEY 07024
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
(201) 585-5100
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
NOT APPLICABLE
(FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT.)
<PAGE>
<PAGE>
ITEM 5. OTHER EVENTS.
The Cooper Companies, Inc. (the 'Company') announced that a verdict had been
reached in the trial with respect to the charges in the federal criminal
indictment against the Company and Gary Singer, a former Co-Chairman of the
Company, relating to, among other things, an alleged securities 'trading
scheme.'
The foregoing is qualified in its entirety by the text of the Company's
press release dated January 14, 1994 which is filed as an exhibit hereto and
incorporated by reference herein.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
<TABLE>
<CAPTION>
EXHIBIT NO. DESCRIPTION
- ------------------ ---------------------------------------------------------------------------------------------
<S> <C>
99.1 Press Release dated January 14, 1994 of The Cooper Companies, Inc.
</TABLE>
<PAGE>
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
THE COOPER COMPANIES, INC.
By:/s/ MARISA F. JACOBS
Marisa F. Jacobs
Secretary and
Associate General Counsel
Date: January 14, 1994
<PAGE>
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
SEQUENTIALLY
EXHIBIT NO. DESCRIPTION NUMBERED PAGE
- ------------------ ---------------------------------------------------------------------------- -------------
<S> <C> <C>
99.1 Press Release dated January 14, 1994 of The Cooper Companies, Inc.
</TABLE>
NEWS RELEASE
The Cooper Companies
1 Bridge Plaza, Sixth Floor
Fort Lee, NJ 07024 USA
201-585-5100
201-585-5355 (Fax)
CONTACTS:
Marisa A. Heine
Peter C. Harkins
D.F. King & Co., Inc.
(212) 269-5550
(212) 952-0137 (Fax)
FOR IMMEDIATE RELEASE
FORT LEE, NEW JERSEY, JANUARY 14, 1994 . . . The Cooper Companies, Inc.
(NYSE:COO)(the 'Company') announced today that a verdict had been reached in the
trial with respect to the charges in the federal criminal indictment against the
Company and Gary Singer, a former Co-Chairman of the Company, relating to, among
other things, an alleged securities 'trading scheme.' Mr. Singer was found
guilty on 21 counts, including racketeering, conspiracy, mail fraud, wire fraud,
money laundering and aiding and abetting violations by an investment advisor.
The Company was found guilty on seven counts of mail fraud and wire fraud
related to Mr. Singer's conduct, but acquitted of conspiracy and aiding
and abetting charges.
Sentencing is expected to occur on March 25, 1994. The maximum penalty
which could be imposed on the Company is the greatest of $500,000 per count,
twice the gross gain derived from each count or twice the gross loss suffered by
the victim of each count. In addition to penalties, the court could impose a
fine equal to restitution.
The Company, Gary Singer and Steven Singer, the Company's Executive Vice
President and Chief Operating Officer, face various related charges contained in
a civil complaint filed by the Securities and Exchange Commission.
NOTE TO EDITOR: The principal subsidiaries of The Cooper Companies, Inc. are
CooperVision, Inc., CooperVision Pharmaceuticals, Inc., CooperSurgical, Inc. and
Hospital Group of America, Inc. See press releases dated October 7, 1993 and
January 7, 1994 for information regarding the Company's recent settlement of
liability for breast implant litigation and completion of an exchange offer and
consent solicitation relating to its 10-5/8% subordinated debentures.
<PAGE>
<PAGE>
